Strides Pharma debuts with ESG rating of 76/100 in the S&P Global’s CSA 2024
Scored 85/100, 2.3x the industry average in Social and 73/100, 1.8x the industry average in Governance
Scored 85/100, 2.3x the industry average in Social and 73/100, 1.8x the industry average in Governance
The revenue from operations in Q3 FY25 is Rs. 8,358.6 crore, up 16% YoY
Olanzapine is indicated for the acute and maintenance treatment of schizophrenia and related psychotic disorders
This study will enrol 210 ALS patients and study doses of 50 mg and 75 mg Usnoflast versus placebo
The change is reflective of the company’s evolving vision aimed at further strengthening its global presence and a commitment to providing innovative solutions in the API and CDMO space
The company ensures a reliable and strong portfolio at competitive prices without compromising on excellent quality
Eculizumab is indicated for the treatment of patients with Paroxysmal Nocturnal Hemoglobinuria and atypical Hemolytic Uremic Syndrome
The brand Magtein by Threotech has a sales value of approximately US $438 million
Jubilant Cadista will submit an appropriate action plan to the USFDA on these observations
Antibe Therapeutics is a clinical-stage biotechnological company developing novel drugs primarily focusing on reducing pain and inflammation
Subscribe To Our Newsletter & Stay Updated